placebo + bromocriptine

The designation placebo + bromocriptine refers to a specific treatment arm used in clinical research, most notably in a Phase 3 trial sponsored by Boehringer Ingelheim comparing pramipexole to bromocriptine in patients with advanced Parkinson's disease. In this double-blind study design, patients in this arm received active bromocriptine along with a placebo version of the experimental drug (pramipexole) to maintain blinding. Bromocriptine is a semi-synthetic ergot alkaloid derivative that functions as a potent dopamine D2 receptor agonist and a partial dopamine D1 receptor agonist. By stimulating postsynaptic dopamine receptors in the striatum, it compensates for the loss of endogenous dopamine, thereby alleviating motor symptoms such as bradykinesia, tremors, and rigidity. While bromocriptine is a well-established, FDA-approved therapy for Parkinson's disease and various endocrine disorders, this specific combination is a trial-specific intervention rather than a standalone commercial product.

Brand names

Parlodel

Other names

Bromocriptine mesylateBromocriptine